Literature DB >> 31900736

Deep brain stimulation for myoclonus dystonia syndrome: a meta-analysis with individual patient data.

Xin Wang1,2, Xinguang Yu3,4.   

Abstract

Good outcomes have been reported in deep brain stimulation (DBS) for myoclonus-dystonia syndrome (M-D), a heritable disease characterized by childhood-onset myoclonic jerks and dystonia in the upper body. This meta-analysis was to evaluate the clinical outcomes consecutively, compare the stimulation targets, and identify potential prognostic factors. A systematic literature search was performed on PubMed, Web of Science, and Embase. The primary outcome was the percent improvement in Burke-Fahn-Marsden Dystonia Rating Scale movement (BFMDRS-M) scores for dystonia and Unified Myoclonus Rating Scale (UMRS) scores for myoclonus at the last follow-up visit. BFMDRS-disability scores of the patients were also summarized. Pearson correlation analyses were performed to identify the myoclonus and dystonia outcome predictors. Thirty-one studies reporting 71 patients were included. There were significant improvements in BFMDRS-M and BFMDRS-disability scores in each time category and at the last follow-up visit. Mean improvement (%) in UMRS was 79.5 ± 18.2, and 94.1% of the patients showed > 50% improvement in UMRS scores at the last follow-up visit. There was a significant trend toward improved myoclonus outcome with older age at onset and shorter disease duration. Most of the adverse events were mild and transient, and pallidal stimulation seemed to be better with respect to fewer stimulation-induced events. Based on the current data, DBS is effective for even the severe M-D. Surgery at an early stage may predict a better outcome. Although targets do not serve as the outcome predictors, pallidal stimulation may be preferred due to fewer stimulation-induced events.

Entities:  

Keywords:  Deep brain stimulation; Globus pallidus internus; Individual patient data; Meta-analysis; Myoclonus dystonia syndrome; Predictive factors; Ventral intermediate nucleus

Mesh:

Year:  2020        PMID: 31900736     DOI: 10.1007/s10143-019-01233-x

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  42 in total

1.  The Unified Myoclonus Rating Scale.

Authors:  Steven J Frucht; Sue E Leurgans; Mark Hallett; Stanley Fahn
Journal:  Adv Neurol       Date:  2002

2.  Effect of pallidal deep brain stimulation on psychiatric symptoms in myoclonus-dystonia due to ε-sarcoglycan mutations.

Authors:  Maria Fiorella Contarino; Elisabeth M Foncke; Danielle C Cath; P Richard Schuurman; Johannes D Speelman; Marina A J Tijssen
Journal:  Arch Neurol       Date:  2011-08

3.  Bilateral deep brain stimulation of the pallidum for myoclonus-dystonia due to ε-sarcoglycan mutations: a pilot study.

Authors:  Julie Azoulay-Zyss; Emmanuel Roze; Marie-Laure Welter; Soledad Navarro; Jérôme Yelnik; Fabienne Clot; Eric Bardinet; Carine Karachi; Didier Dormont; Damien Galanaud; Bernard Pidoux; Philippe Cornu; Marie Vidailhet; David Grabli
Journal:  Arch Neurol       Date:  2011-01

4.  Pallidal and thalamic deep brain stimulation in myoclonus-dystonia.

Authors:  Doreen Gruber; Andrea A Kühn; Thomas Schoenecker; Anatol Kivi; Thomas Trottenberg; Karl-Titus Hoffmann; Alireza Gharabaghi; Ute A Kopp; Gerd-Helge Schneider; Christine Klein; Friedrich Asmus; Andreas Kupsch
Journal:  Mov Disord       Date:  2010-08-15       Impact factor: 10.338

5.  Local field potentials and oscillatory activity of the internal globus pallidus in myoclonus-dystonia.

Authors:  Elisabeth M J Foncke; Lo J Bour; Johannes D Speelman; Johannes H T M Koelman; Marina A J Tijssen
Journal:  Mov Disord       Date:  2007-02-15       Impact factor: 10.338

6.  Frameless robot-assisted pallidal deep brain stimulation surgery in pediatric patients with movement disorders: precision and short-term clinical results.

Authors:  Santiago Candela; María Isabel Vanegas; Alejandra Darling; Juan Darío Ortigoza-Escobar; Mariana Alamar; Jordi Muchart; Alejandra Climent; Enrique Ferrer; Jordi Rumià; Belén Pérez-Dueñas
Journal:  J Neurosurg Pediatr       Date:  2018-07-20       Impact factor: 2.375

7.  Bilateral pallidal deep brain stimulation in myoclonus-dystonia: our experience in three cases and their follow-up.

Authors:  G Fernández-Pajarín; A Sesar; J L Relova; B Ares; I Jiménez-Martín; P Blanco-Arias; M Gelabert-González; A Castro
Journal:  Acta Neurochir (Wien)       Date:  2016-08-17       Impact factor: 2.216

8.  Deep brain stimulation in myoclonus-dystonia syndrome.

Authors:  Laura Cif; Enza Maria Valente; Simone Hemm; Christine Coubes; Nathalie Vayssiere; Stéphanie Serrat; Annalisa Di Giorgio; Philippe Coubes
Journal:  Mov Disord       Date:  2004-06       Impact factor: 10.338

9.  Metabolic changes in DYT11 myoclonus-dystonia.

Authors:  Maren Carbon; Deborah Raymond; Laurie Ozelius; Rachel Saunders-Pullman; Steven Frucht; Vijay Dhawan; Susan Bressman; David Eidelberg
Journal:  Neurology       Date:  2013-01-02       Impact factor: 9.910

10.  Deep Brain Stimulation of the Pallidum is Effective and Might Stabilize Striatal D(2) Receptor Binding in Myoclonus-Dystonia.

Authors:  R J Beukers; M F Contarino; J D Speelman; P R Schuurman; J Booij; Marina A J Tijssen
Journal:  Front Neurol       Date:  2012-02-20       Impact factor: 4.003

View more
  3 in total

Review 1.  GPi-DBS for KMT2B-Associated Dystonia: Systematic Review and Meta-Analysis.

Authors:  Roopa Rajan; Kanwaljeet Garg; Arti Saini; Divya M Radhakrishnan; Miryam Carecchio; Binukumar Bk; Manmohan Singh; Achal K Srivastava
Journal:  Mov Disord Clin Pract       Date:  2021-12-04

Review 2.  ε-Sarcoglycan: Unraveling the Myoclonus-Dystonia Gene.

Authors:  Ana Cazurro-Gutiérrez; Anna Marcé-Grau; Marta Correa-Vela; Ainara Salazar; María I Vanegas; Alfons Macaya; Àlex Bayés; Belén Pérez-Dueñas
Journal:  Mol Neurobiol       Date:  2021-04-22       Impact factor: 5.590

Review 3.  Pallidal Deep Brain Stimulation for Monogenic Dystonia: The Effect of Gene on Outcome.

Authors:  Stephen Tisch; Kishore Raj Kumar
Journal:  Front Neurol       Date:  2021-01-08       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.